Icade Gelecekteki Büyüme
Future kriter kontrolleri 3/6
Icade kazanç ve gelirin sırasıyla yıllık 86.7% ve 1.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 94.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 5.6% olacağı tahmin edilmektedir.
Anahtar bilgiler
86.7%
Kazanç büyüme oranı
94.65%
EPS büyüme oranı
| REITs kazanç büyümesi | 12.0% |
| Gelir büyüme oranı | 1.2% |
| Gelecekteki özkaynak getirisi | 5.62% |
| Analist kapsamı | Good |
| Son güncelleme | 05 Jun 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Anlatı Güncellemesi • Jun 06
ICAD: Limited Downside View Will Still Pressure Shares Going Forward
Analysts have raised their fair value estimate for Icade from €16.30 to €17.00, citing a higher Street price target of €22 and the view that downside risk at current levels now appears more limited. What's in the News Icade has scheduled a Special and Extraordinary Shareholders Meeting for June 10, 2026, at the Coeur Defense building, Tour B Espace Comet, 24th floor, 100 Esplanade du General de Gaulle, Paris La Defense Cedex, France.
Anlatı Güncellemesi • May 22
ICAD: Slower Healthcare Exit And Paused Special Payouts Will Shape Balanced Outlook
Analysts have nudged their fair value estimate for Icade slightly lower to about €21.31. This reflects a reduced price target and updated assumptions around slower revenue growth, a modestly softer profit margin, a higher discount rate and the view that asset disposals and potential special dividends may take longer to materialise.Anlatı Güncellemesi • May 06
ICAD: Slower Healthcare Disposal And Halted Special Payouts Will Pressure Shares
Analysts have reduced their price target on Icade from €30 to €25, citing expectations that the healthcare business disposal could take longer and that special dividends are no longer assumed over the next three years. Analyst Commentary Bearish analysts are flagging a more cautious stance on Icade, with recent research pointing to timing and payout uncertainties that weigh on sentiment.Anlatı Güncellemesi • Apr 21
ICAD: Slower Healthcare Disposal And Lost Special Dividends Will Pressure Shares
Analysts have trimmed their price target for Icade to €25 from €30, reflecting expectations that the planned disposal of the healthcare business may take longer and that special dividends are no longer assumed over the next three years. Analyst Commentary Bearish analysts have shifted to a more cautious stance on Icade, with the rating cut to Equal Weight from Overweight and the price target moved to €25 from €30.Anlatı Güncellemesi • Apr 06
ICAD: Slower Healthcare Disposal And Missing Special Dividends Will Shape Fair Outlook
Narrative Update The analyst price target for Icade has been trimmed to €21.35 from €21.54. This reflects a more cautious stance from analysts after recent downgrades and expectations that healthcare asset disposals and potential special dividends may take longer to play out.
Anlatı Güncellemesi • Mar 23
ICAD: Slower Healthcare Exit And Reset Distributions Will Support Future Repricing
Analysts have trimmed their fair value estimate for Icade to about €29.91 from €31.29, echoing recent price target cuts, such as the move from €30 to €25, as they factor in a longer timeline for healthcare asset disposals and the absence of expected special dividends. Analyst Commentary The recent research updates on Icade point to a more cautious stance as analysts reassess how quickly the group can execute on its healthcare disposals and how generous future shareholder returns might be.Anlatı Güncellemesi • Mar 08
ICAD: Slower Healthcare Disposals And Lost Special Dividends Will Shape Fairly Valued Outlook
Analysts have modestly trimmed their fair value estimate for Icade from €22.03 to about €21.54. This reflects updated views on slower progress on healthcare disposals, a higher required discount rate and the removal of assumed special dividends after recent downgrades and price target cuts on the stock.Anlatı Güncellemesi • Feb 22
ICAD: Higher Office Risk Premium Will Set Stage For Future Repricing
Analysts have reduced their fair value estimate for Icade from about €36.67 to about €31.29, reflecting a higher assumed discount rate and lower profit margin expectations following recent rating cuts and a lower €18 Street price target. Analyst Commentary Recent rating actions on Icade have leaned cautious, with cuts to both recommendations and price targets that feed into the lower fair value estimate.Anlatı Güncellemesi • Feb 08
ICAD: Office Risk Repricing And Downgrades Will Shape Fairly Valued Outlook
Analysts have trimmed their fair value estimate for Icade from €23.33 to €22.03. This reflects a slightly higher discount rate, a modestly lower profit margin outlook and recent downgrades that cite a higher perceived equity risk premium in offices.Anlatı Güncellemesi • Jan 24
ICAD: Office Risk Repricing And Downgrades Will Shape Future Share Performance
Analysts have trimmed their fair value estimate for Icade from about €23.46 to roughly €23.33, citing slightly higher required returns, more cautious assumptions on revenue growth and profit margins, and recent Street downgrades, including a cut in one price target from €25 to €18. Analyst Commentary Bullish Takeaways Bullish analysts may see the recent pullback in fair value and price targets as already reflecting higher equity risk premiums in offices, which can limit further downside if execution on existing projects is steady.Anlatı Güncellemesi • Jan 10
ICAD: Office Downgrades And Higher Risk Premium Will Pressure Shares
Analysts have trimmed their price expectations for Icade to around €14.60, reflecting recent rating downgrades and a higher equity risk premium for office assets. This has been incorporated into updated assumptions for revenue growth, profit margins and future P/E levels.Anlatı Güncellemesi • Dec 26
ICAD: Office Risk Repricing Will Shape Margins And Share Performance
Analysts have lowered their price target on Icade from EUR 25 to EUR 18. This reflects a higher perceived equity risk in offices, alongside slightly faster expected revenue growth but weaker profit margins and a higher valuation multiple.Anlatı Güncellemesi • Dec 12
ICAD: Office Weakness And Higher Equity Risk Will Pressure Shares
Analysts have cut their price target on Icade from EUR 17.80 to EUR 14.60, reflecting a lower revenue growth outlook and higher perceived equity risk in offices, even as profit margins are expected to improve. Analyst Commentary Bearish analysts have recently shifted their stance on Icade, highlighting a weaker outlook for office assets and increasing caution around the company’s equity risk profile.
Yeni Anlatı • Apr 28
Pulse Building Lease With Seine-Saint-Denis Will Boost Portfolio Strength
Improved rental growth expected from the lease agreement and focus on prime locations may enhance revenue stability.Analiz Makalesi • Feb 23
A Look At Icade's (EPA:ICAD) Share Price Returns
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...Analiz Makalesi • Jan 19
How Did Icade SA's (EPA:ICAD) 8.0% ROE Fare Against The Industry?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...Analiz Makalesi • Dec 13
What Type Of Shareholders Make Up Icade SA's (EPA:ICAD) Share Registry?
If you want to know who really controls Icade SA ( EPA:ICAD ), then you'll have to look at the makeup of its share...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 1,381 | 244 | 111 | 181 | 5 |
| 12/31/2027 | 1,327 | 154 | 831 | 208 | 5 |
| 12/31/2026 | 1,302 | 47 | 962 | 253 | 5 |
| 12/31/2025 | 1,337 | -123 | 300 | 300 | N/A |
| 9/30/2025 | 1,338 | -155 | 314 | 314 | N/A |
| 6/30/2025 | 1,339 | -187 | 328 | 328 | N/A |
| 3/31/2025 | 1,376 | -231 | 347 | 347 | N/A |
| 12/31/2024 | 1,412 | -275 | 366 | 366 | N/A |
| 9/30/2024 | 1,468 | -614 | 316 | 316 | N/A |
| 6/30/2024 | 1,523 | -953 | 265 | 265 | N/A |
| 3/31/2024 | 1,524 | -1,121 | 251 | 251 | N/A |
| 12/31/2023 | 1,525 | -1,289 | 238 | 238 | N/A |
| 9/30/2023 | 1,494 | -1,116 | 317 | 317 | N/A |
| 6/30/2023 | 1,464 | -944 | 397 | 397 | N/A |
| 3/31/2023 | 1,467 | -657 | 319 | 319 | N/A |
| 12/31/2022 | 1,469 | -370 | 242 | 242 | N/A |
| 9/30/2022 | 1,496 | -61 | N/A | N/A | N/A |
| 6/30/2022 | 1,524 | 249 | 547 | 224 | N/A |
| 3/31/2022 | 1,586 | 324 | 538 | 377 | N/A |
| 12/31/2021 | 1,648 | 399 | 529 | 529 | N/A |
| 6/30/2021 | 1,640 | 280 | -51 | 600 | N/A |
| 3/31/2021 | 1,534 | 178 | 34 | 625 | N/A |
| 12/31/2020 | 1,429 | 76 | 120 | 650 | N/A |
| 6/30/2020 | 1,458 | 259 | -233 | 453 | N/A |
| 3/31/2020 | 1,485 | 278 | -325 | 411 | N/A |
| 12/31/2019 | 1,512 | 298 | -417 | 369 | N/A |
| 9/30/2019 | 1,587 | 235 | N/A | 358 | N/A |
| 6/30/2019 | 1,662 | 173 | N/A | 346 | N/A |
| 3/31/2019 | 1,717 | 165 | N/A | 351 | N/A |
| 12/31/2018 | 1,773 | 156 | N/A | 356 | N/A |
| 9/30/2018 | 1,714 | 137 | N/A | 372 | N/A |
| 6/30/2018 | 1,655 | 118 | N/A | 387 | N/A |
| 3/31/2018 | 1,642 | 142 | N/A | 362 | N/A |
| 12/31/2017 | 1,629 | 165 | N/A | 337 | N/A |
| 6/30/2017 | 1,596 | 106 | N/A | 255 | N/A |
| 3/31/2017 | 1,542 | 75 | N/A | 235 | N/A |
| 12/31/2016 | 1,487 | 45 | N/A | 215 | N/A |
| 6/30/2016 | 1,391 | -101 | N/A | 309 | N/A |
| 3/31/2016 | 1,411 | -144 | N/A | 307 | N/A |
| 12/31/2015 | 1,431 | -187 | N/A | 305 | N/A |
| 6/30/2015 | 1,649 | 82 | N/A | 526 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: ICAD önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.
Kazançlar ve Piyasa: ICAD önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.
Yüksek Büyüme Kazançları: ICAD önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.
Gelir ve Pazar: ICAD şirketinin gelirinin (yıllık 1.2% ) French pazarından (yıllık 5.7% ) daha yavaş büyümesi öngörülüyor.
Yüksek Büyüme Geliri: ICAD şirketinin gelirinin (yıllık 1.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: ICAD 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 5.6 %).
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/17 20:25 |
| Gün Sonu Hisse Fiyatı | 2026/06/17 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Icade 18 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Celine Huynh | Barclays |
| Paul May | Barclays |
| Aaron Guy | Barclays |